Recent News

• 04.02.2026 - Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
• 03.10.2026 - Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
• 02.18.2026 - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Recent Filings

• 03.10.2026 - EX-99.1 EX-99.1
• 03.10.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2026 - 8-K Current report
• 03.04.2026 - 8-K Current report
• 02.26.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.18.2026 - 8-K Current report
• 02.18.2026 - EX-99.1 EX-99.1
• 02.18.2026 - 8-K Current report
• 02.18.2026 - EX-99.1 EX-99.1
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors